Low-dose aspirin may benefit patients with type 2 diabetes and mild renal dysfunction
TUESDAY, Feb. 22 (HealthDay News) -- Low-dose aspirin therapy may lower the risk of atherosclerotic events in patients with type 2 diabetes with mild renal dysfunction, according to a study published in the February issue of Diabetes Care.
Yoshihiko Saito, M.D., Ph.D., from Nara Medical University in Japan, and colleagues investigated the efficacy of low-dose aspirin for preventing atherosclerotic events in patients with type 2 diabetes and concomitant renal dysfunction. The 2,523 patients enrolled were randomly assigned to two groups, receiving either 81 or 100 mg per day of aspirin, or a nonaspirin group. Stroke, fatal and nonfatal atherosclerotic ischemic heart disease, and peripheral arterial disease were the primary end points in patients followed up for an average of 4.37 years.
The investigators identified a significant interaction between mild renal dysfunction (baseline estimated glomerular filtration rate [eGFR], 60 to 89 mL/min/1.73 m²) and aspirin. In 1,373 patients with eGFR, the primary end point incidence was significantly lower in the aspirin group than in the nonaspirin group (hazard ratio [HR], 0.57). The incidence of primary end points was not affected by aspirin therapy in patients with an eGFR less than 60 mL/min/1.73 m² (HR, 1.3) or in patients with an eGFR greater than or equal to 90 mL/min/1.73 m² (HR, 0.94).
"The current study demonstrated that low-dose aspirin therapy reduced the risk of atherosclerotic events in type 2 diabetic patients with eGFR 60 to 89 mL/min/1.73 m². The results suggest that eGFR may be useful for risk stratification in the primary prevention strategy with aspirin," the authors write.
Several authors reported financial relationships with the pharmaceutical and medical device industries.
Full Text (subscription or payment may be required)